Bloom Energy's Oracle Bet Transforms a Stock Into a $20 Billion Backlog Story

Bloom Energy's backlog nears $20B as AI data centers drive demand; Oracle's Project Jupiter and warrants signal deep strategic ties, but valuation at 20x revenue splits analysts.

The numbers coming out of Bloom Energy are almost too staggering to process. The stock has surged roughly 1,250 percent over the past twelve months, settling around $227 on Tuesday ahead of its first-quarter earnings release. But the real story isn't the share price — it's the backlog.

That order book has swelled by 140 percent year-over-year, pushing toward the $20 billion mark. Management is scrambling to keep pace, planning to double production capacity by the end of 2026. The catalyst is unmistakable: artificial intelligence. Data centers guzzle electricity at unprecedented rates, and when the grid can't deliver fast enough, operators turn to on-site power generation.

Oracle's Desert Bet

The most vivid example of this shift is playing out in New Mexico. Oracle and BorderPlex Digital Assets have completely redesigned their planned AI data center campus, dubbed Project Jupiter. The original plan called for gas turbines and diesel generators. Those are now gone. In their place: Bloom Energy fuel cells with an installed capacity of up to 2.45 gigawatts.

The environmental math is compelling. Bloom's fuel cells emit 92 percent fewer nitrogen oxides than conventional gas turbines. The closed-loop cooling system consumes almost no water in normal operation — a critical advantage in the arid Southwest, where data center operators face strict water usage regulations.

Oracle is already using the technology to power its AI infrastructure for Project Jupiter. But the relationship has deepened beyond that of a typical customer. A recent SEC prospectus supplement reveals that Oracle holds warrants for roughly 3.5 million Bloom shares, with an exercise price of $113.28 per share. With the stock trading well above that level, Oracle has effectively transformed from a pure customer into a potential shareholder. Bloom doesn't receive direct proceeds from those secondary sales, but the strategic endorsement is unmistakable.

The Valuation Tightrope

That backing arrives as the stock trades at roughly 20 times expected annual revenue. Analysts are split on what that's worth. UBS recently lifted its price target to $251 with a buy rating. Barclays pegs fair value at $177 and rates the shares a hold. Jefferies, meanwhile, argues that the Oracle deal alone could absorb Bloom's production capacity through the end of 2027, prompting an upward revision to its target.

For the current fiscal year, management is targeting revenue of up to $3.3 billion and operating profit of up to $475 million. The first quarter consensus calls for $538 million in revenue and earnings of nine cents per share — a noticeable drop from the strong fourth quarter. Bloom has beaten earnings estimates four quarters in a row, so the bar is high.

What Investors Are Watching

The earnings call after the U.S. market close tonight will focus on two critical details. First, management is expected to provide an update on the new 800-volt architecture, a technological upgrade that could improve efficiency. Second, investors want concrete progress on the production expansion timeline.

The gross margin and the precise schedule for Oracle installations will determine how quickly the current AI fantasy translates into actual cash flow. With a $20 billion backlog and a stock that has already priced in years of future growth, the margin for error is razor-thin. Tonight's numbers will show whether Bloom can deliver on its promises — or whether the market has gotten ahead of itself.